Age a Significant Risk Factor for Kidney Function Decline Following Radical Nephrectomy


The findings indicate that nephron sparing management should be prioritized in elderly patients with kidney cancer when it is safe and feasible, according to the study authors.

Age is linked to kidney function decline following radical nephrectomy for kidney cancer, according to findings from a retrospective analysis presented during the 2022 Society of Urologic Oncology Annual Meeting.1

Age linked to decreased kidney function following nephrectomy

Age was an independent risk factor for development of de novo chronic kidney disease after surgical intervention in patients who underwent radical nephrectomy for kidney cancer, according to the lead study author.

The data, according to the study authors, indicate that nephron sparing management should be prioritized in elderly patients when it is safe and feasible.

The study researchers, led by Mimi Vu Nguyen, a medical student at the UC San Diego School of Medicine, conducted the analysis because prior research had not definitively made clear the specific individual impact of age on functional decline after radical nephrectomy.

The results showed how statistical modeling using multivariable logistic regression revealed that compared with patients aged ≤50 years, patients aged 50-70 years (HR, 3.35; P <.001), and patients aged >70 years (HR 7.7; P <.001) had a much greater risk of developing de novo CKD stage 3b chronic kidney disease (CKD) following radical nephrectomy.

Increasing age was also linked to a higher risk of developing de novo CKD stage 3a for both the 50-to-70-years group (HR, 3.4; P <.001) and the >70-years group (HR, 9.4; P <.001). Patients aged >70 years also had an increased risk of developing CKD stage 4 disease (HR, 1.96; P = .027).

Additional research using Kaplan-Meier analysis showed aged-associated declines in 5-year rates of freedom from CKD stage 3a (≤50 years, 73.9%; 50-70 years, 53.7%; and >70 years, 37.06%; P <.001), CKD Stage 3b (≤50 years, 92.7%; 50-70 years, 71.8%; and >70 years, 55.5%; P <.001), and CKD Stage 4 (≤50 years, 93.7%; 50-70 years, 89.8%; and >70 years, 81.2%; P < .001) disease.

Linear-regression analysis also showed that increasing age was significantly correlated with increased delta eGFR (estimated glomerular filtration rate; β = -0.212; P < .001).

“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy,” Nguyen explained in an interview with CancerNetwork®’s sister publication Urology Times. “We also did a linear regression analysis that showed age as being the only independent risk factor for increasing delta eGFR after surgery.

“And so taken together, our findings really suggested in elderly patients with complex renal masses that the recommendation may be to consider less aggressive forms of management, including active surveillance, cryoablation, or partial nephrectomy when it’s safe and feasible, given the increased risk of rapid renal function decline in these older patient cohorts.”

The retrospective review included patients from the International Marker Consortium for Renal Cancer (INMARC) registry who underwent radical nephrectomy. Overall, there were 2436 patients: 513 patients aged ≤50 years; 1344 patients aged 50-70 years; and 579 patients aged >70 years. Patient demographics and characteristics regarding sex, race/ethnicity, baseline BMI, and baseline tumor size were well balanced among the 3 age categories.

The primary end point of the study was the development of de novo CKD stage 3b (eGFR <45 mL/min/1.73m2). Secondary end points included de novo CKD stage 3a (eGFR <60) and de novo stage CKD 4 (eGFR <30).

Of note, the researchers also found that increasing BMI (HR, 1.03; P = .002), coronary artery disease (CAD; HR, 1.70; P = .01), and type 2 diabetes (HR, 1.40; P = .03) were also independent risk factors for de novo CKD stage 3b disease. Increasing BMI (HR, 1.03; P = .002) and CAD (HR, 1.9; P = .015) were also risk factors for de novo CKD stage 3a disease.

Regarding next steps, Nguyen said, “We’re looking into more granular data to differentiate between the different continuous age groups and potentially determine what could be a specific age threshold we could recommend that would be best to pursue less aggressive forms of management.”


Nguyen MV, Walia A, Saidian A, et al. Impact of Age on Functional Decline Following Radical Nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC). Presented at: Society of Urologic Oncology 23rd Annual Meeting; November 30-December 2; San Diego, California. Abstract 141.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content